Label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the usual experimental platform for label-free quantification (LFQ) in discovery proteomics: unlabeled digests enter a chromatography system, ionize at the mass spectrometer interface, and yield MS1 and MS/MS data that software turns into relative protein tables (Bantscheff et al. 2012). In project language, label-free LC-MS/MS names matched prep, separate injections, locked chromatography and acquisition settings, and a declared analysis chain. It is not a metabolomics service definition, not a substitute for chemical tagging when multiplex design requires tags, and not an absolute amount assay without targeted calibration (Gerber et al. 2003). The guide below integrates label-free LC-MS/MS within LFQ workflows, parameters, limits, and project fit. It is not a vendor instrument catalog, not a clinical biomarker promise page, and not a step-by-step software manual for every search engine.

LFQ outputs from label-free LC-MS/MS remain relative contrasts across predefined groups unless follow-up uses stable isotope-labeled internal standard (SIS) or parallel reaction monitoring (PRM) on named peptides. Switching gradient family, injection load, or acquisition mode mid cohort without a new analysis record splits comparability (Cox et al. 2014).

In MtoZ Biolabs offerings, unlabeled discovery commonly runs on label-free LC-MS/MS as data-dependent acquisition (DDA) LFQ from MS1 areas or as unlabeled data-independent acquisition (DIA) when windowed schedules fit the cohort block.

Definition and metric language appear in What Is Label-Free Analysis?. Method routes appear in Mass Spectrometry-Based Quantitative Proteomics: Labeled and Label-Free Quantification Strategies.

What Label-Free LC-MS/MS Covers in LFQ Projects

Four experimental layers belong in the brief when LC-MS/MS carries LFQ.

Sample and digest scope is label-free: no isobaric or metabolic tags on discovery injections. Matched pretreatment from harvest through injection-ready load is part of the LC-MS/MS record.

Liquid chromatography scope separates peptides before ionization. Gradient length, column chemistry, flow path, and load must stay stable across the cohort block that shares one contrast.

Mass spectrometry acquisition scope covers MS1 survey maps and MS/MS triggering or windowed fragmentation. DDA selects precursors in real time. DIA or SWATH-style plans use declared m/z windows with cycle time locked across runs (Gillet et al. 2012).

Informatics scope covers database search, false discovery rate (FDR) control, feature extraction, normalization, missing-value policy, and contrast statistics on frozen groups only.

Label-free LC-MS/MS is the coupled chromatography and tandem MS experiment that feeds LFQ tables. It does not replace contrast design, replicate count, or interleaved run order.

Prep discipline before injection appears in Quantitative Protein Analysis.

Label-Free LC-MS/MS Versus Other Quantitative LC-MS/MS Routes

Chemistry and acquisition can be chosen independently.

Labeled LC-MS/MS discovery uses metabolic encoding such as stable isotope labeling by amino acids in cell culture (SILAC) or isobaric tagging such as tandem mass tag (TMT) before or at injection. Those routes fit closed multiplex designs, not every open enrollment cohort on separate unlabeled injections.

Label-free DDA LFQ on LC-MS/MS integrates MS1 precursor chromatograms after peptide identification. Stochastic precursor selection drives missing values at low abundance.

Label-free DIA on LC-MS/MS quantifies from extracted fragment traces under unified FDR. It often raises completeness in some matrices after pilot evidence but still needs matched prep and one processing chain.

Targeted PRM or multiple reaction monitoring (MRM) on a closed peptide list is a separate LC-MS/MS assay scope, not a synonym for open LFQ discovery.

Unlabeled DIA depth compares with Label-Free DIA Quantitative Proteomics. Chemistry choice compares with Protein Quantification Method.

End-to-End Workflow for Label-Free LC-MS/MS LFQ

A practical label-free LC-MS/MS LFQ spine usually runs as follows.

1. Confirm matrix, contrast, relative claim, and whether DDA LFQ or unlabeled DIA fits the question.
2. Prepare matched digests to injection-ready loads without discovery tags.
3. Lock column, gradient, and load targets from a pilot when matrix is new.
4. Schedule separate LC-MS/MS injections with interleaved order across groups when cohort size allows.
5. Acquire raw files under a frozen acquisition template for the cohort block.
6. Search and control FDR with declared enzyme, modification, and database settings.
7. Extract label-free features; roll peptides to proteins with a declared rule.
8. Normalize and apply missing-value policy; run matrix QC before contrast statistics.
9. Test predefined contrast only; archive instrument methods and processing version with deliverables.

Steps 1 through 5 are LC-MS/MS experimental layers. Steps 6 through 9 are informatics layers when LFQ is in scope.

Figure 1. Label-free LC-MS/MS delivers raw maps and fragment evidence; LFQ comparability depends on locked LC and acquisition settings before statistics.

Quality gates across the same spine appear in How to Improve Data Quality and Reproducibility in Label-Free Proteomics?. Normalization choices appear in How to Normalize Data in Label-Free Quantitative Proteomics?.

LC-MS/MS Parameters That Must Be Locked for LFQ

Layer	Parameter that must be declared	Failure mode if ignored
Digest	Enzyme, reduction, alkylation, cleanup	Peptide pools shift between arms
Load	Mass on column per injection	Compression or ion suppression
Chromatography	Column ID, gradient, temperature	Retention drift breaks alignment
Acquisition	DDA or DIA template, cycle time	Mixed modes in one matrix
MS1	Resolution and scan rate policy	Incomparable peak shapes
MS/MS	Collision energy and isolation	Fragment yield drift
Search	Database, FDR, modifications	Mixed identification spaces
Quant	Precursor or fragment feature rule	Incomparable intensities
Normalization	Method and study groups	Global drift read as biology
Contrast	Frozen before tuning	Post hoc relabeling

Limits follow the same table. Label-free LC-MS/MS does not remove batch confounding when run order tracks treatment. Complex matrices still show dropout in DDA LFQ (Lazar et al. 2016). High load can narrow dynamic range without fixing low-abundance detection.

Reproducibility remediation appears in How to Overcoming Reproducibility Issues in Label-Free Proteomics?. Processing tool context appears in Tools for Label-free Peptide Quantification.

How to Choose Label-Free LC-MS/MS Settings and Follow-On Pipelines

Use matrix pilot, enrollment pattern, acquisition evidence, and follow-up unit together.

Project need	Label-free LC-MS/MS plan that often fits	Recheck before committing
Open cohort, staggered enrollment	DDA LFQ, interleaved injections	Mid-block gradient change
Pilot shows high DDA missingness	Unlabeled DIA or SWATH-style LC-MS/MS	DDA when DIA adds little
Closed arms, one labeling day	TMT or iTRAQ labeled LC-MS/MS	Forced LFQ when multiplex required
Biofluid with depletion	Matched depletion then LFQ	Depletion on one arm only
Thermo DDA with PD in scope	Locked Proteome Discoverer chain	Mixed processors mid contrast
External mixed models	Export-compatible peptide tables	Manual table edits
Amount on named peptides	Targeted SIS or PRM LC-MS/MS	Discovery LFQ ratios as clinical amount

Figure 2. Choose label-free LC-MS/MS LFQ when unlabeled separate injections and locked LC settings fit the contrast; tagging, DIA, or targeted LC-MS/MS fit other claim patterns.

Enrollment checks appear in Exploring Quantitative Analysis in Proteomics. DDA processing with Proteome Discoverer compares with Proteome Discoverer Label-Free Quantification.

Teams with matrix documentation, contrast map, and acquisition pilot results can review the MtoZ Biolabs Label-Free Quantitative Proteomics Service for label-free LC-MS/MS alignment when declared in the project record.

Frequently Asked Questions

1. Is label-free LC-MS/MS the same as LFQ?

No. Label-free names unlabeled separate injections. LFQ names relative quantification from extracted intensities after search and normalization. LC-MS/MS is the instrument experiment that produces the raw data.

2. Does label-free LC-MS/MS cover metabolomics?

This page focuses on proteomics LFQ. Metabolite LC-MS/MS uses different chemistries, libraries, and claim units even when the hardware looks similar.

3. Can injection load be raised to fix low-abundance proteins?

Higher load can increase signal for abundant peptides but may compress dynamic range or overload chromatography. Pilot load and QC plots should precede full cohort scaling.

4. Should DDA and DIA files be merged in one LFQ matrix?

Not without treating each acquisition mode as a separate block with documented bridging if required.

5. When should projects move from label-free LC-MS/MS discovery to targeted LC-MS/MS?

When peptide names freeze and decisions need scheduled remeasurement, SIS-supported amount, or specification-style reporting on a closed list.

MtoZ Biolabs can discuss label-free LC-MS/MS planning when contrast design, locked methods, and follow-up goals are documented.

If further evaluation of DDA versus unlabeled DIA pilots, normalization choice, or discovery-to-targeted staging is needed, project details can be submitted for a feasibility review.

Reference

1. S.A. Gerber, J. Rush, O. Stemman, M.W. Kirschner, S.P. Gygi (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A., 100, 6940-6945. https://doi.org/10.1073/pnas.0832254100
2. M. Bantscheff, S. Lemeer, H.U. Haab, B. Kuster (2012). Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem., 404, 939-965. https://doi.org/10.1007/s00216-012-5892-4
3. J. Cox, M.Y. Hein, C.A. Luber, I. Paron, M. Mann (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics, 13, 2513-2526. https://doi.org/10.1074/mcp.M113.031031
4. L.C. Gillet, P. Navarro, S. Tate, H. Rost, N. Selevsek, L. Reiter, R. Bonner, R. Aebersold (2012). Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics, 11, O111.016717. https://doi.org/10.1074/mcp.O111.016717
5. C. Lazar, L. Gatto, M. Ferro, C. Bruley, T. Burger (2016). Accounting for the multiple natures of missing values in label-free quantitative proteomics data sets to compare imputation strategies. J. Proteome Res., 15, 1116-1125. https://doi.org/10.1021/acs.jproteome.5b00981